Aveo Pharmaceuticals (AVEO) 0.84 $AVEO
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 11:44AM CST
CALX: 8.65 (-0.03), NES: 3.52 (+0.13), RVP: 5.14 (-0.42), RL: 135.20 (-0.60), SR: 1.25 (+0.08), MWA: 9.19 (+0.09), OHGI: 1.82 (-0.12), GENE: 8.04 (+1.90), CALI: 1.35 (+0.06), WPRT: 6.06 (+0.26), RSYS: 2.15 (+0.05), EGLT: 10.60 (+0.58), PACB: 6.96 (-0.06), ACHN: 10.89 (-0.20), BBSI: 39.78 (+0.84), AVEO: 0.84 (-0.06), CBLI: 3.24 (+0.05), ENG: 1.85 (-0.06), PLNR: 6.63 (-0.07)
CAR-T Vs ErbB3 Market Opportunity Comparison
Decision Analytics - Seeking Alpha - Wed Jan 21, 12:32PM CST
CAR-T therapy, also known as "Adoptive Immunotherapy", has been the result of significant investor excitement recently. One look at the stock charts for JUNO and KITE is illustrative of this optimism. While this enthusiasm may be warranted,...
MACK: 10.22 (+0.40), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), BLCM: 20.00 (-0.81), KITE: 62.59 (+0.82), AVEO: 0.84 (-0.06), JUNO: 40.52 (+0.18), GSK: 47.94 (+1.99), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
AVEO to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 12, 5:30AM CST
AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 12:00PM (PT) in San Francisco.
JPM: 59.67 (+0.10), AVEO: 0.84 (-0.06)
New medical chief at Aveo
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 7:06AM CST
AVEO: 0.84 (-0.06)
AVEO Names Michael N. Needle, M.D., As Chief Medical Officer
Business Wire - Fri Jan 09, 5:30AM CST
AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Michael N. Needle, M.D., to the position of Chief Medical Officer. In this role, Dr. Needle, a board certified hematologist/oncologist, will take a leadership role in evaluating clinical development strategies for advancement of the Company's partnered and proprietary pipeline programs. He will report to Michael Bailey, AVEO's president and chief executive officer.
AVEO: 0.84 (-0.06)
AVEO Receives Confirmation of Eligibility for Submission of a Tivozanib Marketing Authorization Application to the European Medicines Agency
Business Wire - Thu Jan 08, 5:30AM CST
AVEO Oncology (NASDAQ:AVEO) today announced that it has received written confirmation from the European Medicine Agency (EMA) that tivozanib is eligible for submission of an application for a European Union Marketing Authorization under the Agency's centralized procedure. Confirmation of eligibility was given in response to the submission of a letter of intent enabling the Company to evaluate the opportunity for submitting a Marketing Authorization Application (MAA) for tivozanib with the EMA for the treatment of renal cell carcinoma (RCC). Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) with a long half-life and activity against all three VEGF receptors. Tivozanib has previously been granted orphan drug designation in Europe for the treatment of RCC.
AVEO: 0.84 (-0.06)
Aveo names new chief amid restructuring
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 8:19AM CST
AVEO: 0.84 (-0.06)
AVEO Announces Executive Transition and Corporate Restructuring
Business Wire - Wed Jan 07, 5:30AM CST
--Company to Eliminate Internal Research Function to Align Corporate Resources with the Company's Future Strategic Plans
AVEO: 0.84 (-0.06)
Aveo up on (old) news of Klarman stake
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 11:00AM CST
OPHT: 51.11 (+0.12), AVEO: 0.84 (-0.06)
The New Baupost Biotech Picks
Matthew Finston - at Seeking Alpha - Mon Dec 15, 8:53AM CST
BIIB: 391.66 (-0.45), FWP: 22.66 (-0.09), MRK: 58.81 (-0.07), AVEO: 0.84 (-0.06), IDIX: 24.50 (+0.05), ATRA: 18.00 (-0.10), THRX: 14.85 (+1.00), TBPH: 18.51 (+0.28), PRTK: 26.95 (+0.65), KIN: 6.79 (-0.21), KERX: 11.63 (-0.60)
Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST
OCN: 9.10 (+0.09), KOS: 9.05 (+0.10), KIN: 6.79 (-0.21), VSAT: 62.71 (+0.53), RFMD: 16.59 (-0.35), EBAY: 56.47 (+1.73), TQNT: 27.55 (-0.77), IDIX: 24.50 (+0.05), SEMI: 22.21 (+1.36), VRTV: 52.58 (-0.82), THRX: 14.85 (+1.00), TBPH: 18.51 (+0.28), IMOS: 23.95 (-0.01), ELOS: 10.16 (+0.07), MU: 31.85 (-0.09), AR: 40.34 (+0.69), NCQ: 0.56 (+0.03), PBF: 30.18 (+0.27), LNG: 74.48 (+0.90), ATRA: 18.00 (-0.10), KERX: 11.63 (-0.60), NG: 3.96 (+0.03), AOI: 1.05 (+0.03), FWP: 22.66 (-0.09), BYD: 14.36 (-0.23), ALDW: 17.45 (-0.06), SUNE: 21.45 (+0.30), MRK: 58.81 (-0.07), AVEO: 0.84 (-0.06), AIG: 53.96 (+1.51)
AVEO Gains on Tivozanib Agreement with Ophthotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:20PM CST
AVEO Pharmaceuticals' (AVEO) shares gained around 10.9% ever since the company announced a deal with Ophthotech (OPHT).
OPHT: 51.11 (+0.12), AVEO: 0.84 (-0.06), AMAG: 41.49 (+0.23)
Aveo licenses tivozanib to Ophthotech
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:55AM CST
OPHT: 51.11 (+0.12), AVEO: 0.84 (-0.06)
AVEO Enters into Research and Exclusive Option Agreement with Ophthotech for Tivozanib (VEGF inhibitor) for the Treatment of Ocular Diseases
Business Wire - Tue Nov 11, 5:42AM CST
AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO's small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye.
AVEO: 0.84 (-0.06), OPHT: 51.11 (+0.12)
AVEO Pharmaceuticals misses by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:55PM CST
AVEO: 0.84 (-0.06)
Will AVEO Pharmaceuticals (AVEO) Surprise this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 4:10PM CST
AVEO Pharmaceuticals (AVEO), which is expected to report third-quarter 2014 results on Nov 6, had delivered a positive earnings surprise of 7.89% last quarter.
BIIB: 391.66 (-0.45), AVEO: 0.84 (-0.06), INFI: 15.13 (+0.55), HSP: 87.35 (unch)
AVEO Oncology Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 3:17PM CST
AVEO Oncology (NASDAQ:AVEO) today reported its third quarter 2014 financial results and provided an overview of its progress toward achieving its strategic plan.
AVEO: 0.84 (-0.06)
Global Cancer Kinase Inhibitors Market & Pipeline Insight 2014: 649 Pipeline Drugs & 35 Marketed Drugs
M2 - Mon Oct 13, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/btwzfw/global_cancer) has announced the addition of the "Global Cancer Kinase Inhibitors Market & Pipeline Insight" report to their offering. The recent years have witnessed the emergence of kinase inhibitors, which have the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past two decades, the researchers have increased their learning about the functioning of these inhibitors, which has led to the achievement of significant milestones of development during this period. The use of inhibitors for treating cancer is gradually increasing. The rising market availability of these agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body's acceptance of inhibitors so as to develop more efficient drugs. The field of cancer is growing mainly because of the globally aging population, increasing rates of obesity and rising smoking rates across all regions. This opens the door of opportunities for the drug makers globally because the kinase inhibitors is highly competitive and is currently in growing stages, thus offering significant areas of unmet medical need. The future years are likely to witness significantly increased levels of activity in the development of these drugs. Additionally, with the industry undergoing the period of patent cliff, the pharma companies are rapidly working towards filling up their exhausting pipelines with alternative and innovative drugs. Kinase inhibitors fit these spaces most appropriately, which is likely to drive future growth and improve the survival rates of cancer patients. Global Cancer Kinase Inhibitors Market & Pipeline Insight Report Highlights: - Classification & Mechanism of Kinase Inhibitors - Cancer Kinase Inhibitors Therapy Market Overview - Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country - Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country - Patent Analysis & Orphan Designation of Kinase Inhibitors - Cancer Kinase Inhibitors In Clinical Pipeline: 649 Drugs - Marketed Cancer Kinase Inhibitors: 35 Drugs Key Topics Covered: 1. Introduction to Kinase Inhibitors 2. Kinase Inhibitors Classification 3. Mechanisms of Kinase Inhibitors 4. Need for Cancer Kinase Inhibitor Therapy 5. Cancer Kinase Inhibitors Therapy Market Overview 6. Cancer Kinase Inhibitors Therapy Market Dynamics 7. Cancer Kinase Inhibitors Therapy Market Future Outlook 8. Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country 9. Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country 10. Suspended & Discontinued in Cancer Kinase Inhibitors Therapy Pipeline 11. Competitive Landscape - AVEO Pharmaceuticals - Amgen - AstraZeneca - Bayer HealthCare Pharmaceuticals - Boehringer Ingelheim - Deciphera Pharmaceuticals - Genentech - GlaxoSmithKline - Incyte Corporation - Novartis - Pfizer - Takeda For more information visit http://www.researchandmarkets.com/research/bt...bal_cancer
INCY: 75.94 (+0.28), AVEO: 0.84 (-0.06), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
HILL, AVEO, ORBC Expected To Be Down Before Next Earnings Releases
M2 - Tue Oct 07, 5:22AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and December earnings reports. Dot Hill Systems Corp (NASDAQ:HILL), Aveo Pharmaceuticals Inc (NASDAQ:AVEO), ORBCOMM Inc (NASDAQ:ORBC) are all expected to be Down Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down Before earnings are released Thursday:
HILL: 4.42 (+0.06), AVEO: 0.84 (-0.06), ORBC: 5.83 (+0.21)
AVEO-Biodesix Reveal Lung Cancer Study Exploratory Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 2:30PM CDT
AVEO Pharmaceuticals, Inc. (AVEO) and Biodesix announced data from an exploratory analysis of patients suffering from non small cell lung cancer (NSCLC) in a phase II study on ficlatuzumab.
MDVN: 104.71 (+0.67), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), AVEO: 0.84 (-0.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 11:44AM CST
CALX: 8.65 (-0.03), NES: 3.52 (+0.13), RVP: 5.14 (-0.42), RL: 135.20 (-0.60), SR: 1.25 (+0.08), MWA: 9.19 (+0.09), OHGI: 1.82 (-0.12), GENE: 8.04 (+1.90), CALI: 1.35 (+0.06), WPRT: 6.06 (+0.26), RSYS: 2.15 (+0.05), EGLT: 10.60 (+0.58), PACB: 6.96 (-0.06), ACHN: 10.89 (-0.20), BBSI: 39.78 (+0.84), AVEO: 0.84 (-0.06), CBLI: 3.24 (+0.05), ENG: 1.85 (-0.06), PLNR: 6.63 (-0.07)
CAR-T Vs ErbB3 Market Opportunity Comparison
Decision Analytics - Seeking Alpha - Wed Jan 21, 12:32PM CST
CAR-T therapy, also known as "Adoptive Immunotherapy", has been the result of significant investor excitement recently. One look at the stock charts for JUNO and KITE is illustrative of this optimism. While this enthusiasm may be warranted,...
MACK: 10.22 (+0.40), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), BLCM: 20.00 (-0.81), KITE: 62.59 (+0.82), AVEO: 0.84 (-0.06), JUNO: 40.52 (+0.18), GSK: 47.94 (+1.99), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17)
AVEO to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 12, 5:30AM CST
AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 12:00PM (PT) in San Francisco.
JPM: 59.67 (+0.10), AVEO: 0.84 (-0.06)
New medical chief at Aveo
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 7:06AM CST
AVEO: 0.84 (-0.06)
AVEO Names Michael N. Needle, M.D., As Chief Medical Officer
Business Wire - Fri Jan 09, 5:30AM CST
AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Michael N. Needle, M.D., to the position of Chief Medical Officer. In this role, Dr. Needle, a board certified hematologist/oncologist, will take a leadership role in evaluating clinical development strategies for advancement of the Company's partnered and proprietary pipeline programs. He will report to Michael Bailey, AVEO's president and chief executive officer.
AVEO: 0.84 (-0.06)
AVEO Receives Confirmation of Eligibility for Submission of a Tivozanib Marketing Authorization Application to the European Medicines Agency
Business Wire - Thu Jan 08, 5:30AM CST
AVEO Oncology (NASDAQ:AVEO) today announced that it has received written confirmation from the European Medicine Agency (EMA) that tivozanib is eligible for submission of an application for a European Union Marketing Authorization under the Agency's centralized procedure. Confirmation of eligibility was given in response to the submission of a letter of intent enabling the Company to evaluate the opportunity for submitting a Marketing Authorization Application (MAA) for tivozanib with the EMA for the treatment of renal cell carcinoma (RCC). Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) with a long half-life and activity against all three VEGF receptors. Tivozanib has previously been granted orphan drug designation in Europe for the treatment of RCC.
AVEO: 0.84 (-0.06)
Aveo names new chief amid restructuring
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 8:19AM CST
AVEO: 0.84 (-0.06)
AVEO Announces Executive Transition and Corporate Restructuring
Business Wire - Wed Jan 07, 5:30AM CST
--Company to Eliminate Internal Research Function to Align Corporate Resources with the Company's Future Strategic Plans
AVEO: 0.84 (-0.06)
Aveo up on (old) news of Klarman stake
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 11:00AM CST
OPHT: 51.11 (+0.12), AVEO: 0.84 (-0.06)
The New Baupost Biotech Picks
Matthew Finston - at Seeking Alpha - Mon Dec 15, 8:53AM CST
BIIB: 391.66 (-0.45), FWP: 22.66 (-0.09), MRK: 58.81 (-0.07), AVEO: 0.84 (-0.06), IDIX: 24.50 (+0.05), ATRA: 18.00 (-0.10), THRX: 14.85 (+1.00), TBPH: 18.51 (+0.28), PRTK: 26.95 (+0.65), KIN: 6.79 (-0.21), KERX: 11.63 (-0.60)
Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST
OCN: 9.10 (+0.09), KOS: 9.05 (+0.10), KIN: 6.79 (-0.21), VSAT: 62.71 (+0.53), RFMD: 16.59 (-0.35), EBAY: 56.47 (+1.73), TQNT: 27.55 (-0.77), IDIX: 24.50 (+0.05), SEMI: 22.21 (+1.36), VRTV: 52.58 (-0.82), THRX: 14.85 (+1.00), TBPH: 18.51 (+0.28), IMOS: 23.95 (-0.01), ELOS: 10.16 (+0.07), MU: 31.85 (-0.09), AR: 40.34 (+0.69), NCQ: 0.56 (+0.03), PBF: 30.18 (+0.27), LNG: 74.48 (+0.90), ATRA: 18.00 (-0.10), KERX: 11.63 (-0.60), NG: 3.96 (+0.03), AOI: 1.05 (+0.03), FWP: 22.66 (-0.09), BYD: 14.36 (-0.23), ALDW: 17.45 (-0.06), SUNE: 21.45 (+0.30), MRK: 58.81 (-0.07), AVEO: 0.84 (-0.06), AIG: 53.96 (+1.51)
AVEO Gains on Tivozanib Agreement with Ophthotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:20PM CST
AVEO Pharmaceuticals' (AVEO) shares gained around 10.9% ever since the company announced a deal with Ophthotech (OPHT).
OPHT: 51.11 (+0.12), AVEO: 0.84 (-0.06), AMAG: 41.49 (+0.23)
Aveo licenses tivozanib to Ophthotech
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:55AM CST
OPHT: 51.11 (+0.12), AVEO: 0.84 (-0.06)
AVEO Enters into Research and Exclusive Option Agreement with Ophthotech for Tivozanib (VEGF inhibitor) for the Treatment of Ocular Diseases
Business Wire - Tue Nov 11, 5:42AM CST
AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO's small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye.
AVEO: 0.84 (-0.06), OPHT: 51.11 (+0.12)
AVEO Pharmaceuticals misses by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:55PM CST
AVEO: 0.84 (-0.06)
Will AVEO Pharmaceuticals (AVEO) Surprise this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 4:10PM CST
AVEO Pharmaceuticals (AVEO), which is expected to report third-quarter 2014 results on Nov 6, had delivered a positive earnings surprise of 7.89% last quarter.
BIIB: 391.66 (-0.45), AVEO: 0.84 (-0.06), INFI: 15.13 (+0.55), HSP: 87.35 (unch)
AVEO Oncology Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 3:17PM CST
AVEO Oncology (NASDAQ:AVEO) today reported its third quarter 2014 financial results and provided an overview of its progress toward achieving its strategic plan.
AVEO: 0.84 (-0.06)
Global Cancer Kinase Inhibitors Market & Pipeline Insight 2014: 649 Pipeline Drugs & 35 Marketed Drugs
M2 - Mon Oct 13, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/btwzfw/global_cancer) has announced the addition of the "Global Cancer Kinase Inhibitors Market & Pipeline Insight" report to their offering. The recent years have witnessed the emergence of kinase inhibitors, which have the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past two decades, the researchers have increased their learning about the functioning of these inhibitors, which has led to the achievement of significant milestones of development during this period. The use of inhibitors for treating cancer is gradually increasing. The rising market availability of these agents has enabled the pharmaceutical companies to develop novel combination approaches which have the capability to provide even greater insight into the body's acceptance of inhibitors so as to develop more efficient drugs. The field of cancer is growing mainly because of the globally aging population, increasing rates of obesity and rising smoking rates across all regions. This opens the door of opportunities for the drug makers globally because the kinase inhibitors is highly competitive and is currently in growing stages, thus offering significant areas of unmet medical need. The future years are likely to witness significantly increased levels of activity in the development of these drugs. Additionally, with the industry undergoing the period of patent cliff, the pharma companies are rapidly working towards filling up their exhausting pipelines with alternative and innovative drugs. Kinase inhibitors fit these spaces most appropriately, which is likely to drive future growth and improve the survival rates of cancer patients. Global Cancer Kinase Inhibitors Market & Pipeline Insight Report Highlights: - Classification & Mechanism of Kinase Inhibitors - Cancer Kinase Inhibitors Therapy Market Overview - Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country - Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country - Patent Analysis & Orphan Designation of Kinase Inhibitors - Cancer Kinase Inhibitors In Clinical Pipeline: 649 Drugs - Marketed Cancer Kinase Inhibitors: 35 Drugs Key Topics Covered: 1. Introduction to Kinase Inhibitors 2. Kinase Inhibitors Classification 3. Mechanisms of Kinase Inhibitors 4. Need for Cancer Kinase Inhibitor Therapy 5. Cancer Kinase Inhibitors Therapy Market Overview 6. Cancer Kinase Inhibitors Therapy Market Dynamics 7. Cancer Kinase Inhibitors Therapy Market Future Outlook 8. Cancer Kinase Inhibitors Therapy Pipeline by Phase, Indication, Company & Country 9. Marketed Cancer Kinase Inhibitors Therapy by Indication, Company & Country 10. Suspended & Discontinued in Cancer Kinase Inhibitors Therapy Pipeline 11. Competitive Landscape - AVEO Pharmaceuticals - Amgen - AstraZeneca - Bayer HealthCare Pharmaceuticals - Boehringer Ingelheim - Deciphera Pharmaceuticals - Genentech - GlaxoSmithKline - Incyte Corporation - Novartis - Pfizer - Takeda For more information visit http://www.researchandmarkets.com/research/bt...bal_cancer
INCY: 75.94 (+0.28), AVEO: 0.84 (-0.06), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
HILL, AVEO, ORBC Expected To Be Down Before Next Earnings Releases
M2 - Tue Oct 07, 5:22AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released in the coming weeks and determining how the stocks have performed Before their last 12 quarterly, 6 quarterly and December earnings reports. Dot Hill Systems Corp (NASDAQ:HILL), Aveo Pharmaceuticals Inc (NASDAQ:AVEO), ORBCOMM Inc (NASDAQ:ORBC) are all expected to be Down Before their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down Before earnings are released Thursday:
HILL: 4.42 (+0.06), AVEO: 0.84 (-0.06), ORBC: 5.83 (+0.21)
AVEO-Biodesix Reveal Lung Cancer Study Exploratory Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 02, 2:30PM CDT
AVEO Pharmaceuticals, Inc. (AVEO) and Biodesix announced data from an exploratory analysis of patients suffering from non small cell lung cancer (NSCLC) in a phase II study on ficlatuzumab.
MDVN: 104.71 (+0.67), GILD: 101.90 (+1.10), AZN: 69.96 (+0.20), AVEO: 0.84 (-0.06)
